Global Idiopathic Pulmonary Fibrosis Market: Key Highlights
Global Idiopathic Pulmonary Fibrosis Market: Key Market Dynamics
Request Sample PDF Here: https://www.forencisresearch.com/idiopathic-pulmonary-fibrosis-market-sample-pdf/
Global Idiopathic Pulmonary Fibrosis Market: Regional Overview
Growing healthcare sector with the increasing prevalence of IPF patients in the region is driving the market growth. As per Cleveland Clinic statistics, around 50,000 of the total US population is suffering from Idiopathic pulmonary fibrosis (IPF) along with the high incidence of estimated 15,000 new cases annually. Increasing aged population in the region drives the market growth. Population Reference Bureau stated that 52 million of the total US population are old/aged (60 years or more) and is expected to rise till 95 million by 2060. The shifting demographics of the country towards the aged and older population is driving the IPF prevalence.
Asia-Pacific is one of the promising regions in the IPF market owing to the rise in the incidence of smokers in the region. Tobacco smoking is one of the prime cause of respiratory diseases in the region, which is expected to drive the demand for IPF treatment market. Increase in prevalence of fibrotic diseases with the rising elderly population with higher spending on healthcare in the region drives the market growth.
Global Idiopathic Pulmonary Fibrosis Market: Key Players Overview
F. Hoffmann-La Roche Ltd is the Switzerland based healthcare company operates globally through a vast product portfolio. The company operates through two business segment, therapeutics and diagnostics product range. F. Hoffmann-La Roche Ltd offers Esbriet, an oral anti-fibrotic drug for treating the Idiopathic Pulmonary Fibrosis (IPF) patients. U.S. Food and Drug Administration (FDA) and the European Commission in 2017 approved the Esbriet 801 mg and 267 mg tablets as an alternative capsule formulation. In March 2020, US FDA granted Breakthrough Therapy Designation (BTD) to Esbriet (pirfenidone) for the adult patients with unclassifiable interstitial lung disease (uILD).
Boehringer Ingelheim International GmbH is the pharmaceutical company with global headquarters in Ingelheim am Rhein, Germany. The company delivers products dedicated for enhancing human and animal health. It delivers products [PK1] for cardiovascular, oncology, respiratory, nervous system, metabolic and others. The company offers Idiopathic pulmonary fibrosis (IPF) treatment products, under the brand name: OFEV with approval in USA, Brazil, Canada, Japan and other countries.
About Forencis Research
Forencis Research is a B2B market research, intelligence and advisory firm engaging in market research and consulting services across leading industries, globally. Our robust and meticulous research team provides high growth and niche syndicated reports, customized reports and consulting reports to the diverse global fortune clientele and intellectual institutions. Forencis Research database is a constantly evolving pool of market research reports and white paper studies which helps companies to foster accelerated revenue growth in global and regional markets.
Our robust research methodology is designed to constantly map the high growth markets in various industries. This facilitates enhanced decision-making capabilities to our clients. Our robust research methodology is designed to constantly map the high growth markets in various industries. This facilitates enhanced decision-making capabilities to our clients. We strive to help our clients to foray into uncharted space to attain increased revenue growth for the present as well as the future.
Phone: +1 (720) 306 9020